Stock Analiz

Ironwood Pharmaceuticals Inc. IRWD

Biotechnology: Pharmaceutical Preparations · IPO 2010 · data as of November 13, 2026

$4.83Market cap $800M
Open the interactive analysis →

Ironwood Pharmaceuticals Inc. (IRWD) is a healthcare company listed in the US with a market value of about $800M. In the twelve months to September 30, 2026 it had revenue of $400M and net income of $150M, a net margin of 37.4%.

Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is value (4/5); the weakest is track record (1/5).

Key numbers: a P/E of 5.4, a price to free cash flow of 3.9, 5-year revenue growth of -5% a year, a 5-year average ROIC of 30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 184% above the current price.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2010. Revenue went from $76M in 2014 to $296M in 2025, growth of about 13.1% a year. It was profitable in 6 of the last 10 years in our data. Its share count fell by 13% over three years (buybacks). It spends 32% of revenue on research and development.

Score: 2.2 / 5

Value4/5
Future growth2/5
Track record1/5
Financial health2/5
Shareholder returns2/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year average ROIC above 12%
  • Positive free cash flow

Checks not passed

  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • Profitable 5 years in a row
  • ROE above 15%

Valuation

P/E (TTM)5.4
Forward P/E3.3
P/FCF3.9
P/S2.0
P/B—
EV/EBITDA4.1
PEG—
Dividend yield0.00%
FCF yield25.7%
Shareholder yield0.0%
Intrinsic value vs. price+184%

Growth and quality

Revenue growth (1 yr)-15.7%
Revenue growth (5 yrs, per year)-5.3%
EPS growth (5 yrs, per year)-25.7%
FCF growth (3 yrs, per year)-22.6%
Net margin (5-yr avg.)-9.5%
ROIC (5-yr avg.)30.1%
Profitable years (of last 10)6
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$400M$296M$351M$443M$411M$414M$390M$428M$347M$298M$274M
Net income$150M$24M$880000-$1.0B$175M$528M$106M$22M-$282M-$117M-$82M
Free cash flow$205M$127M$103M$183M$274M$262M$167M$4M-$71M-$104M-$30M
EPS (diluted)$0.90$0.15$0.01$-6.45$0.96$3.21$0.66$0.14$-1.85$-0.78$-0.56
Net margin37.4%8.1%0.2%-226.4%42.6%127.7%27.3%5.0%-81.5%-39.2%-29.8%
ROIC—57.1%——16.2%17.0%27.0%35.5%-323.2%-7.7%-13.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $6.17, 28% above the current price; targets range from $3.70 to $10.00; the consensus rating is “Buy”; expected EPS is $1.30 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Ironwood Pharmaceuticals’s P/E ratio?

About 5.4, based on the last twelve months of diluted earnings per share (forward P/E about 3.3).

Is Ironwood Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 184% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Ironwood Pharmaceuticals pay a dividend?

Not currently.

Is Ironwood Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Ironwood Pharmaceuticals scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.